News & Events zu Sunshine Biopharma Inc (SBFM)SBFMSunshine Biopharma Inc

Sunshine Biopharma Prices Public Offering at $6 Million

Sunshine Biopharma announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The offering consists of 10,909,083 Common Units, each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.66. The public offering price per Common Unit is $0.55. Aegis Capital Corp. is acting as the exclusive placement agent for the offering.

Sunshine Biopharma Launches 4mg and 8mg Ondansetron Generics in Canada

Sunshine Biopharma has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Ondansetron is widely prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering two strengths and film-coated tablets, healthcare providers can better tailor the treatment to individual patient needs and physical condition.

Sunshine Biopharma Advances Coronavirus Drug Candidate into IND Studies

Sunshine Biopharma announces that it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The Company had previously published laboratory results on its library of Anti-Coronavirus compounds in August 2024 and more recently in March 2026. The drug candidate the company nominated for advanced development displayed nanomolar potency against the viral protease and had broad-spectrum activity against other SARS-CoV-2 variants of concerns in vitro. It exhibited desirable ADME profiles and was assessed in a general mammalian toxicology study in rats. Our drug candidate had high oral bioavailability in mice, rats and dogs. In Addition, it was preferentially enriched in the lungs of both mice and rats. In the K18-hACE2 mice infected with human SARS-CoV-2 virus, repeated oral administrations of the drug candidate significantly suppressed pulmonary viral replication in a dose-dependent manner.